Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04379518 · ClinicalTrials.gov registry record · Phase 1
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04379518 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 4 participants.
The verdict
NCT04379518, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.
Interventions
- BIOLOGICAL Recombinant Interferon Alfa-2b
- DRUG Rintatolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2023-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04379518
The ClinicalTrials.gov registry entry for NCT04379518 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Recombinant Interferon Alfa-2b is the first listed.
NCT04379518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04379518 about?
NCT04379518 is a clinical study titled "Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients". This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rint...
What is the current status of trial NCT04379518?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-11-17. Estimated completion is 2023-03-15.
What interventions are being tested in trial NCT04379518?
The interventions under investigation include: Recombinant Interferon Alfa-2b (BIOLOGICAL), Rintatolimod (DRUG).
Who is sponsoring clinical trial NCT04379518?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.